A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
Clinical data | |
---|---|
ATC code |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C28H28ClF2N3O |
Molar mass | 496.00 g·mol−1 |
3D model (JSmol) | |
| |
|
Clopimozide (R-29,764) is a typical antipsychotic drug of the diphenylbutylpiperidine class.[1][2] It is very potent and has an extremely long duration of action, lasting at least one week with a single dose.[3][4][5] It was developed by Janssen Pharmaceutica but was never marketed.
See alsoedit
Referencesedit
- ^ De Cuyper HJ, Van Praag HM, Mulder WR (May 1979). "Therapeutical significance of clopimozide in the treatment of chronic psychotic patients". Acta Psychiatrica Scandinavica. 59 (5): 561–74. doi:10.1111/j.1600-0447.1979.tb00256.x. PMID 37697. S2CID 30954603.
- ^ Knapen J, Bollen J, Brugmanns J, Rombaut N (1976). "Treatment of chronic psychoses with oral clopimozide". Acta Psychiatrica Belgica (in French). 76 (4): 644–57. PMID 798469.
- ^ Janssen PA, Niemegeers CJ, Schellekens KH, Lenaerts FM, Wauquier A (August 1975). "Clopimozide (R 29 764), a new highly potent and orally long-acting neuroleptic of the diphenylbutylpiperidine series". Arzneimittel-Forschung. 25 (8): 1287–94. PMID 1242360.
- ^ Floru L, Tegeler J (1978). "Clinical experiments with the new oral long-acting neuroleptic clopimozide (R 29 764)". Arzneimittel-Forschung. 28 (2): 341–4. PMID 25071.
- ^ Bobon J, Parent M, Toussaint C, Pinchard A (1976). "Long-acting neuroleptics. IV. Preliminary study of clopimozide (R 29764)". Acta Psychiatrica Belgica (in French). 76 (1): 138–43. PMID 970182.
D1-like |
| ||||||
---|---|---|---|---|---|---|---|
D2-like |
|